Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

PURPOSE: The CLEOPATRA (Clinical Evaluation of Trastuzumab and Pertuzumab) study demonstrated superior progression-free survival (PFS) and overall survival when pertuzumab was added to trastuzumab and docetaxel. Paclitaxel given once per week is effective and less toxic than docetaxel. We performed...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Dang, Chau, Iyengar, Neil, Datko, Farrah, D'Andrea, Gabriella, Theodoulou, Maria, Dickler, Maura, Goldfarb, Shari, Lake, Diana, Fasano, Julie, Fornier, Monica, Gilewski, Theresa, Modi, Shanu, Gajria, Devika, Moynahan, Mary Ellen, Hamilton, Nicola, Patil, Sujata, Jochelson, Maxine, Norton, Larry, Baselga, José, Hudis, Clifford
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5747317/
https://ncbi.nlm.nih.gov/pubmed/25547504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.1745
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky